Journal: Journal of Thoracic Disease

Article Title: Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis

doi: 10.21037/jtd-21-913

Figure Lengend Snippet: The ROC curve of the CapitalBio DNA microarray for detecting RFP resistance. ROC, receiver operating characteristic; RFP, rifampicin.

Article Snippet: The results were recorded by a LuxScan 10K microarray scanner (CapitalBio).

Techniques: Microarray

Journal: Journal of Thoracic Disease

Article Title: Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis

doi: 10.21037/jtd-21-913

Figure Lengend Snippet: Diagnostic performance of DNA microarray for RFP resistance

Article Snippet: The results were recorded by a LuxScan 10K microarray scanner (CapitalBio).

Techniques: Diagnostic Assay, Microarray

Journal: Journal of Thoracic Disease

Article Title: Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis

doi: 10.21037/jtd-21-913

Figure Lengend Snippet: The ROC curve of the CapitalBio DNA microarray for detecting INH resistance. ROC, receiver operating characteristic; IHN, isonicotinic acid hydrazide.

Article Snippet: The results were recorded by a LuxScan 10K microarray scanner (CapitalBio).

Techniques: Microarray

Journal: Journal of Thoracic Disease

Article Title: Diagnostic performance of DNA microarray for detecting rifampicin and isoniazid resistance in Mycobacterium tuberculosis

doi: 10.21037/jtd-21-913

Figure Lengend Snippet: Diagnostic performance of DNA microarray for INH resistance

Article Snippet: The results were recorded by a LuxScan 10K microarray scanner (CapitalBio).

Techniques: Diagnostic Assay, Microarray

Journal: Nature Biotechnology

Article Title: Chinese health biotech and the billion-patient market

doi: 10.1038/nbt0108-37

Figure Lengend Snippet: Chinese health biotech firms interviewed and their product/technology portfolios a

Article Snippet: CapitalBio , Joint R&D and commercialization programs in China with Affymetrix (Santa Clara, CA, USA) for gene expression profiling and genotyping services (including the development of an advanced GeneChip-compatible point-of-care system) using Affymetrix's photolithographically synthesized oligonucleotide chip technology. Provided non-exclusive rights to Alpha Innotech (San Leandro, CA, USA) for marketing of CapitalBio's microarray laser scanner. Deal to undertake joint product development, manufacturing in China, technology transfer, services and products mutual representation with BioTools (Madrid). Deal to distribute Becton Dickinson (Franklin Lakes, NJ, USA) products in China. Exclusive rights to distribute certain products from Enzo Biochem (New York), BioMachines (Research Triangle Park, NC, USA), Aviva Systems Biology (San Diego), Macherey-Nagel (Düren, Germany), Advalytix (Brunnthal, Germany) in China. Exclusive rights to MediBic (Tokyo) to market CapitalBio's pharmacogenomic services in Japan. Exclusive rights to distribute certain CapitalBio products given to Greenmate Biotech (Seoul, Korea) in Korea, FK Biotec (Port Alegre, Brazil) in Brazil and VitroLab (Istanbul, Turkey) in Turkey. Nonexclusive distribution rights to certain CapitalBio products provided to TechnoConcept (New Delhi, India) and Viswagen Biotech (Kerala, India) in India and Australian Biosearch (Karrinyup, Australia) in Australia..

Techniques: Recombinant, Produced, Expressing, Enzyme-linked Immunosorbent Assay, Diagnostic Assay, Sandwich ELISA, Marker, Incubation, Cell Culture, Microarray, Software, Immunoprecipitation, Injection, Functional Assay, Calcium Assay, Clone Assay, Hybridization, Immunohistochemistry, Transgenic Assay, Knock-Out, Sequencing, Real-time Polymerase Chain Reaction, Genetically Modified, Histone Deacetylase Assay, In Vivo, Modification, Plasmid Preparation, Isolation, Mutagenesis, In Situ Hybridization, DNA Sequencing, Animal Model

Journal: Nature Biotechnology

Article Title: Chinese health biotech and the billion-patient market

doi: 10.1038/nbt0108-37

Figure Lengend Snippet: Collaborations/partnerships between companies interviewed and foreign entities

Article Snippet: CapitalBio , Joint R&D and commercialization programs in China with Affymetrix (Santa Clara, CA, USA) for gene expression profiling and genotyping services (including the development of an advanced GeneChip-compatible point-of-care system) using Affymetrix's photolithographically synthesized oligonucleotide chip technology. Provided non-exclusive rights to Alpha Innotech (San Leandro, CA, USA) for marketing of CapitalBio's microarray laser scanner. Deal to undertake joint product development, manufacturing in China, technology transfer, services and products mutual representation with BioTools (Madrid). Deal to distribute Becton Dickinson (Franklin Lakes, NJ, USA) products in China. Exclusive rights to distribute certain products from Enzo Biochem (New York), BioMachines (Research Triangle Park, NC, USA), Aviva Systems Biology (San Diego), Macherey-Nagel (Düren, Germany), Advalytix (Brunnthal, Germany) in China. Exclusive rights to MediBic (Tokyo) to market CapitalBio's pharmacogenomic services in Japan. Exclusive rights to distribute certain CapitalBio products given to Greenmate Biotech (Seoul, Korea) in Korea, FK Biotec (Port Alegre, Brazil) in Brazil and VitroLab (Istanbul, Turkey) in Turkey. Nonexclusive distribution rights to certain CapitalBio products provided to TechnoConcept (New Delhi, India) and Viswagen Biotech (Kerala, India) in India and Australian Biosearch (Karrinyup, Australia) in Australia..

Techniques: Expressing, Synthesized, Microarray, Functional Assay, Western Blot, Luminex, Histone Deacetylase Assay, Software